Product Description
Metroprolol succinate 98418-47-4
AI Product Description
*The following content is generated by AI and is for reference only.
Metoprolol succinate is a widely prescribed beta-adrenergic blocking agent belonging to the selective beta-1 receptor antagonist class. Its molecular formula is C₁₅H₂₅NO₃, and it is identified by the CAS number 37964-80-2 for the free base form, though commercial preparations often exist as tartrate salts. This medication is primarily utilized in the management of cardiovascular disorders, offering significant therapeutic benefits through its ability to slow the heart rate and reduce myocardial oxygen demand.
The primary clinical indications for metoprolol succinate include the treatment of hypertension, where it helps lower blood pressure to prevent strokes and heart attacks. It is also a cornerstone therapy for chronic stable angina pectoris, effectively reducing the frequency of chest pain episodes by improving cardiac efficiency. Furthermore, this extended-release formulation is indicated for the management of heart failure with reduced ejection fraction, as it has been proven to improve survival rates and reduce hospitalization risks in patients with symptomatic heart failure. The succinate salt specifically allows for once-daily dosing due to its controlled-release mechanism, ensuring steady plasma concentrations throughout the day and enhancing patient compliance compared to immediate-release versions.
Pharmacologically, metoprolol succinate works by selectively blocking beta-1 adrenergic receptors located mainly in the heart. By inhibiting the binding of catecholamines like epinephrine, it decreases heart rate, contractility, and conduction velocity. This reduction in cardiac workload alleviates strain on the cardiovascular system. While generally well-tolerated, common side effects may include fatigue, dizziness, bradycardia, and cold extremities. It is contraindicated in patients with severe bradycardia, heart block, or cardiogenic shock. As with all potent cardiovascular medications, dosage adjustments are often necessary based on individual patient response and renal function. Overall, metoprolol succinate remains a vital component in modern cardiology, providing effective long-term control for various life-threatening conditions when used under strict medical supervision.